Shenzhen Salubris Pharmaceuticals Co., Ltd.

SZSE:002294 Voorraadrapport

Marktkapitalisatie: CN¥37.1b

Shenzhen Salubris Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Shenzhen Salubris Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 1.2% per year. Shenzhen Salubris Pharmaceuticals's return on equity is 7.1%, and it has net margins of 15.6%.

Belangrijke informatie

6.8%

Groei van de winst

5.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei-1.2%
Rendement op eigen vermogen7.1%
Nettomarge15.6%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Sep 02
We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Recent updates

We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

Sep 02
We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings

What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Aug 23
What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You

Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Aug 02
Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?

Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

May 22
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up

A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Apr 17
A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)

Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Feb 28
Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?

Opbrengsten en kosten

Hoe Shenzhen Salubris Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SZSE:002294 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 243,9106111,673459
30 Jun 243,7245871,530447
31 Mar 243,5695691,415439
31 Dec 233,3655801,305409
30 Sep 233,3905771,224432
30 Jun 233,4986271,271453
31 Mar 233,4346111,278516
01 Jan 233,4826371,335534
30 Sep 223,4196811,474502
30 Jun 223,3506451,499475
31 Mar 223,2286161,461378
01 Jan 223,0585341,340357
30 Sep 212,7921851,192318
30 Jun 212,5791011,095324
31 Mar 212,638661,062369
31 Dec 202,739611,179371
30 Sep 203,0412661,390436
30 Jun 203,6502791,603706
31 Mar 204,1485441,809721
31 Dec 194,4707151,855763
30 Sep 194,6811,0251,739703
30 Jun 194,7411,3011,775454
31 Mar 194,7141,3641,683435
31 Dec 184,6521,4581,578407
30 Sep 184,5871,5081,580401
30 Jun 184,3861,5111,285513
31 Mar 184,3081,4911,344419
31 Dec 174,1541,4521,336327
30 Sep 174,1061,4511,311225
30 Jun 173,9761,4321,3860
31 Mar 173,8911,4151,2660
31 Dec 163,8331,3961,2160
30 Sep 163,7391,3801,1410
30 Jun 163,7111,3411,1530
31 Mar 163,6101,3101,1030
31 Dec 153,4781,2661,0580
30 Sep 153,4671,2171,0380
30 Jun 153,2371,1669660
31 Mar 153,0151,1029260
31 Dec 142,8831,0429020
30 Sep 142,6869898660
30 Jun 142,5709338400
31 Mar 142,4508838130
31 Dec 132,3278307750

Kwaliteitswinsten: 002294 has high quality earnings.

Groeiende winstmarge: 002294's current net profit margins (15.6%) are lower than last year (17%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 002294's earnings have grown by 6.8% per year over the past 5 years.

Versnelling van de groei: 002294's earnings growth over the past year (5.9%) is below its 5-year average (6.8% per year).

Winst versus industrie: 002294 earnings growth over the past year (5.9%) exceeded the Pharmaceuticals industry -1.2%.


Rendement op eigen vermogen

Hoge ROE: 002294's Return on Equity (7.1%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden